콜레라 백신 시장 보고서 : 백신 유형, 제품 유형, 최종사용자, 지역별(2026-2034년)

The global cholera vaccines market size reached USD 6.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 14.3 Million by 2034, exhibiting a growth rate (CAGR) of 8.85% during 2026-2034. The market is experiencing steady growth driven by rising cholera cases, particularly in regions with poor sanitation and hygiene, the accelerating supportive government policies and funding across the globe, and continuous technological advancements in vaccine technology.

CHOLERA VACCINES MARKET ANALYSIS:

• Major Market Drivers: The growing incidents of cholera outbreaks in areas with inadequate sanitation and lack of access to clean water drive the market. It is also supported due to efforts taken by the government and substantial investments in vaccine campaigns by global health organizations.
• Key Market Trends: Some of the cholera vaccines market trends include the newer group of cholera vaccines. The new products offer better results and are longer-lasting. A tool of this capacity is a game changer, particularly in resource-poor settings. Moreover, the shift of single and long-term vaccines makes them cheaper and more convenient.
• Geographical Trends: High demand for cholera vaccines is seen in endemic areas of Africa, Asia, and parts of the Americas, where the burden of disease is most severe. International organizations, together with governments in the class, have made vaccination campaigns a priority to prevent and stem cholera outbreaks.
• Competitive Landscape: The cholera vaccine market is a dynamic industry with key players such as Valneva SE, Sanofi, and Eubiologics Co., Ltd leading the charge. These companies invest heavily in research and development, constantly encouraging the envelope with new techniques.
• Challenges and Opportunities: One of the main challenges is the complex system of vaccination in remote and underdeveloped areas, which affects vaccination coverage. However, this acts as one of the cholera vaccines market recent opportunities and is supported by funding for international health organizations to attend so, has advanced vaccine technology and improved its development.

CHOLERA VACCINES MARKET TRENDS:

Increasing awareness and cholera prevention

According to an article in the National Library of Medicine, the disease is responsible for an estimated 2.9 million (1.3-4 million) global prevalence and 95,000 (21,000-143,000) deaths, with 60% and 29% of cases reported in Sub-Saharan Africa and South-East Asia, respectively. As communities learn how deadly cholera episodes can be, the shift for proper prevention including vaccines is accelerating. The growing use of vaccines in cholera prevention and the promotion of mnemonic vaccination is thus expanding the cholera vaccines industry. The increasing awareness brought about by public health campaigns, education, and popular media helps close the knowledge gap, which is crucial in preventing the continued spread of cholera. In addition, the increasing interest in vaccination on a personal level and a grassroots community level is encouraging government, healthcare organizations, and international agencies to drive resource allocation to vaccination campaigns, thereby pushing market growth.

Advancements in vaccine technology

The continuous improvements in vaccine technology are also key to the expansion of the market. Along with this, newer oral cholera vaccines (OCVs) are offering more efficacious and cost-effective immunization tools. According to the cholera vaccines market analysis, improvements in the new antiviral drugs are aiding the second-generation vaccines to be even more potent, achieve longer-term protection, and be more convenient to deliver. Their single-dose regimens and capability to maintain in difficult storage conditions for long periods are improving their attractiveness. In addition, continuous research and development initiatives are launching new vaccines in the future, which is, therefore, aiding in the market expansion as well as the successful eradication of cholera.

Supportive government policies and funding

According to the cholera vaccines market overview, supportive government policies and rising funding from international organizations are one of the major factors driving the market. Along with this, the national authorities across cholera-endemic areas are applying health policies and vaccination plans to control the spread of cholera. In addition, international health organizations support massive campaigns. Its objectives are to maintain high vaccination coverage, especially in areas with endemic circulation. Moreover, the process of licensing and the swift deployment of vaccines are crucial for controlling cholera-related emergencies, significantly fueling cholera vaccines market growth. In addition, the global focus on strengthening public health infrastructure and preventive healthcare systems is providing for a sustained demand for cholera vaccines across the world.

CHOLERA VACCINES MARKET SEGMENTATION:

Breakup by Vaccine Type:

• Whole Cell V. Cholerae O1 with Recombinant B-Subunit
• Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit dominates the market

The whole cell V. cholerae O1 with recombinant B-subunit holds the largest cholera vaccines market share. It consists of whole cells of the Vibrio cholerae O1 strain, inactivated by formalin and combined with the recombinant B subunit of cholera toxin. The efficacy, oral vaccine preparations, and dual systemic and mucosal immunization efficacy of this formulation are responsible for dominance. Furthermore, the long-term shelf life and lowered cold chain requirements of this vaccine render it an appealing vaccine regimen for deployment in endemic as well as limited resource settings. As it is highly efficacious, and efficient, and can prevent disease outbreaks at source, governments and health organizations are emphasizing its use in mass vaccination campaigns, bolstering the cholera vaccines demand.

Breakup by Product:

• Dukoral
• Shanchol
• Vaxchora
• Euvichol and Euvichol-Plus
• Others

Dukoral dominates the market

The cholera vaccines segment is further categorized into Dukoral, an oral cholera vaccine (OCV), which has the highest acceptance and efficacy. Also, Dukoral (developed by Valneva SE) provides dual protection against both cholera and traveler's diarrhea due to enterotoxigenic Escherichia coli (ETEC), which is especially important for those traveling to endemic areas. Therefore, it has a large share of cholera vaccines market revenue. The combination vaccine leads to improved immunization due to broad immunity induced by killed whole cells of Vibrio cholerae O1 combined with a recombinant cholera toxin B subunit. Worldwide approval of the vaccine, including from major regulatory authorities such as the World Health Organization (WHO) and the European Medicines Agency (EMA), further supports its global availability. Furthermore, supported by effective marketing strategies and well-established distribution networks are intensifying the market. It is licensed in endemic as well as non-endemic areas and is also leading the global cholera vaccine market according to the cholera vaccines market forecast.

Breakup by End User:

• Hospitals and Clinics
• Research and Academic Laboratories
• Others

Hospitals and clinics dominate the market

Cholera vaccines fall into the category of vaccines and are purchased by common consumers, agencies, and corporations as well as hospitals and clinics, which are the largest end-user segment in the market. In addition, continuous advancements in vaccine technology are one of the cholera vaccines market recent developments. Along with this, hospitals and clinics would have the capacity in terms of cold storage and well-trained medical staff for vaccine storage and administration. Their existing social connections and confidence also help to accomplish a higher uptake of vaccination, especially in the more cholera-prone regions. In addition, these institutions are frequently partners in government and international health organizations' efforts to control cholera epidemics. Hospitals and clinics are responsible for making vaccines widely available and getting individuals vaccinated by providing routine immunization services and preparing to respond quickly to an epidemic. Therefore, they are certain to remain the most prevailing end users in the cholera vaccine market, the cholera vaccines market report states.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the cholera vaccines industry include

• Astellas Pharma Inc.
• Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
• Emergent BioSolutions Inc.
• Eubiologics Co. Ltd.
• Johnson & Johnson
• Merck & Co. Inc.
• Pfizer Inc.
• PharmaChoice Canada Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Valneva SE

Major players in the market continue to develop and expand their market presence associated with licensing agreements, product launches, and novel distribution networks. Cholera vaccines companies are targeting its advanced oral cholera vaccine to expand its availability in endemic settings. They also are highlighting building up their supply chain and expanding their product offering to fill global health gaps. In addition, their capabilities to develop affordable and effective vaccines are crucial in targeting underserved populations, thereby addressing significant health disparities in regions most affected by cholera. Moreover, they are collaborating with government and non-governmental partners to enhance vaccination programs for comprehensive and coordinated cholera prevention and control efforts which is creating a positive cholera vaccines market outlook.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cholera Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Vaccine Type

• 6.1 Whole Cell V. Cholerae O1 with Recombinant B-Subunit
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Killed Oral O1 and O139
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Product

• 7.1 Dukoral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Shanchol
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Vaxchora
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Euvichol and Euvichol-Plus
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research and Academic Laboratories
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Astellas Pharma Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Emergent BioSolutions Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Eubiologics Co. Ltd.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Johnson & Johnson
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Merck & Co. Inc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Pfizer Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 PharmaChoice Canada Inc
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Sanofi S.A.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Takeda Pharmaceutical Company Limited.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Valneva SE
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials